chrisvoncsefalvay/vaers-outcomes huggingface dataset:
The patient presented to the pharmacy for his booster dose of covid vaccine.  He had not set up an appointment online so we accepted him as a walk in.  He had to be added into our system.  The technician processed the information through the computer.  Once in the vaccine room the pharmacist asked the patient if he was here for his booster dose of Pfizer vaccine.  He replied yes.  He was also asked about side effects he experienced with his first two doses.  He said he was expecting more side effects but did just fine with the first two doses.  After the vaccine was administered the pharmacist counseled the patient on taking a picture of his vaccine card to have on hand and then to store his card in a safe place at home.  He asked if his card was filled out and the pharmacist asked to see it.  Immediately it was noted that the first 2 doses that the patient received were Moderna.  The pharmacist told the patient to call the pharmacy back if he experienced any problems or had any questions.  Fifteen minutes after his dose he was doing just fine and continued shopping in the grocery section of our store.
pt recvd vax & had inc t 102; not walking;  dragging leg where inject was given;
Pt. site is hot, red, itchy. Induration is aprox. 6x10 cm
Moderna COVID-19 Vaccine EUA: I had a low-grade headache, felt weak, and had three one-hour naps on 30Apr2021. *Because of having a specific Watch, it looked like my heart rate was elevated too. *; About 4 am on 01May21, I had some chills and broke out in a sweat. Since I got up, I'm starting to feel pretty normal.
Flu like symptoms for 24 hrs, plus very large swelling under left arm.  Tylenol for treatment. Flu like symptoms abated but swelling under left has gotten larger.
EPILEPSY, UNSPECIFIED TRANSIENT CEREBRAL ISCHEMIA 12/3/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Employee came to vaccine clinic on 10/28 for his COVID BOOSTER. He did not have his covid card with him but attested that it had been 6 mo since 3nd shot. Pfizer booster was given at that time. When put into system it was noted that he was 2 weeks early from needing the booster. PH contacted their director.  What symptoms were reported? (check all that apply) Chills~Fatigue (Feeling Very Tired)~Muscle or Body Aches
The next day post vax, the pt developed an injection site reaction characterized by a 50-mm area of induration, redness, and warmth. This is one of two pts from this facility who experienced an adverse event following receipt of vax. Additional information indicated that the pt developed cellulitis with a fever greater than 101. She was seen by the physician and prescribed Keflex. The pt recovered.
the minute she shot me there was pain; swollen lymph nodes; side of head hurts; This case was reported by a consumer via call center representative and described the occurrence of pain in a 59-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On 4th August 2020, the patient received the 2nd dose of Shingrix. On an unknown date, immediately after receiving Shingrix, the patient experienced pain, enlargement of lymph nodes and headache. On an unknown date, the outcome of the pain was recovered/resolved and the outcome of the enlargement of lymph nodes and headache were unknown.   It was unknown if the reporter considered the pain, enlargement of lymph nodes and headache to be related to Shingrix.  Additional details were provided as follows: The patient received Shingrix and was told she was too early, pharmacist was not ready, but administered the shot anyway.  The reporter stated that the minute the pharmacist shot patient there was pain and was resolved.  The patient also had swollen lymph node and side of head hurts. The reporter did not consent to follow up.
Information has been received from a physician concerning a 60 year old male patient with hypercholesterolaemia, coronary artery disease and hypertension and history of chickenpox as a child and coronary artery bypass and no allergies who on 16-MAY-2007 was vaccinated SC in the left arm deltoid muscle with 0.65 ml dose of Zostavax (Lot # 656606/0033U). Concomitant therapy included LIPITOR, NIASPAN, aspirin (unspecified), DIOVAN and TOPROL XL TABLETS. The patient did not have any recent exposure to chickenpox and shingles. On 17-MAY-2007, day after vaccination, the patient developed "virus symptoms". Approximately 2 to 3 days later the patient developed a rash on his back. The patient was seen in office on 24-MAY-2007 and it was noted that the rash was on the back at T7. The patient was diagnosed with shingles. The patient was treated with VALTREX. At the time of report, the patient was recovering. A product quality complaint was not involved. Additional information has been received from the physician who reported that the patient presently on 30-MAY-2007 had welts but not vesicular lesions. The physician reported that the patient developed cold and runny nose, one day after vaccination. By 19-MAY-2007, the patient developed a slight rash and an uncomfortable feeling on left front side of chest around T7. The patient also felt welts on his back. The physician stated that he would wait a few days and bring the patient back into the office to obtain a specimen. The patient was enrolled in the VZVIP program: the Varicella Zoster Virus Identification Program enables biological samples to be analyzed by PCR to identify if ZVZ is present and if it is present to identify whether it is associated with the wild-type VZV strain or with the vaccine VZV strain. The specimen was sent to the laboratory on 01-JUN-2007 and the source of specimen, was from vesicular lesions. It was reported that on 24-MAY-2007 the patient developed shingles and had body temperature of 101 degree Fahrenheit. Other systemic symptoms were coryza, fever, chills and flu like illness. Herpes zoster was marked by vesicular rash with 50 lesions on left lower chest dermatome (T7) from the back to the left on left side of the sternum. The rash did not occur at the site of injection. The patient rated his pain a 10 on a scale of 0 to 10 with 10 being the highest. A direct fluorescent antibody test was not undertaken. A specimen for polymerase chain reaction test was collected and the results were pending. A photo of lesions was also taken. The patient was recovering on VALTREX. Additional information has been requested. Follow-up received on 03/27/2009. The physician stated that PCR test was done and it was wild type.
Information has been received from a medical assistant concerning a 82 year old male patient who on 11-OCT-2006 was vaccinated with a dose of Pneumovax 23 (lot #651319/1007P).  Concomitant therapy included influenza virus vaccine (unspecified), administered at the same visit in separate arms (separate sites).  On approximately 11-OCT-2006 the patient developed a reaction in arm where the Pneumovax 23 vaccine was administered, that ranged from redness to blotchiness to pain.  Medical attention was sought.  Subsequently, the patient was feeling better.  The medical assistant requested a lot check.  No product quality complaint was involved.  The reporter indicated there were other patients who developed similar reactions after Pneumovax 23 vaccine was administered.  Follow up information has been received from the Certified Medical Assistant concerning the retired patient with an allergy to an unspecified "numbing medication" who on the morning of 11-OCT-2006 was vaccinated IM in right deltoid with a dose of Pneumovax 23 (lot #651319/1007P).  He received a dose of FLUVIRIN on the same morning in the left deltoid.  On the same day, the patient developed pain and redness in the right arm for several days.  The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory.  The lot met the requirements of the agency and was released.  Additional information is not expected.
Patient received 0.5mL dose of Moderna COVID 6m-11y formulation due to overfill of single-dose vial. Patient was discharged in stable condition with no adverse symptoms reported at time of vaccination.
Extreme nausea, dizziness, and feeling off balance.  Brain fog/inability to concentrate. Extreme sensitivity to motion. Cannot move around without feeling nauseas/ill. Symptoms sometime "come and go" in extreme waves. (feeling fine one moment, followed by severe nausea). Brain fog and dizziness subsided after 3 weeks. All other symptoms still extremely severe and ongoing.
Information has been received from a 61 year old male with a history of open heart surgery and no allergies who on approximately 12-AUG-2008, also reported as 2 weeks ago, was vaccinated with a 0.65 mL dose of ZOSTAVAX (lot number, injection site and route not reported). Concomitant therapy included a lot of unspecified medications for diabetes and heart disease. On approximately 14-AUG-2008, also reported as 2-3 days after vaccination, the patient experienced severe pain in his hip and can hardly walk. Therapy with ZOSTAVAX was discontinued. Unspecified medical attention was sought. The patient's event's persisted. No further information is available.
Red area to (R) upper arm 2" (L) x 1" (W) no pain, no itching, no edema no treatment.
This case was reported by a physician via sales rep and described the occurrence of injection site pain in a male patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received SHINGRIX at an unknown dose. On an unknown date, less than a month after receiving SHINGRIX, the patient experienced injection site pain and influenza-like symptoms. On an unknown date, the outcome of the injection site pain and influenza-like symptoms were recovered/resolved. It was unknown if the reporter considered the injection site pain and influenza-like symptoms to be related to SHINGRIX. Additional details were reported as follows: The age at vaccination was not reported. The field representative calling to report that physician was the patient. The field representative stated that physician had the SHINGRIX shot in the last thirty days and had pain at the injection site and flu like symptoms that lasted 2 to 3 days. No further details reported.
Patient experienced arm pain following first and second injections for 24 - 48 hours; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from a sales representative. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: PAIN IN EXTREMITY (non-serious), outcome "recovered" (2021), described as "Patient experienced arm pain following first and second injections for 24 - 48 hours".  Clinical course: Patient experienced arm pain following first and second injections for 24 - 48 hours. Patient also experienced nausea, dry heaves and fatigue for 24 hours after second dose.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER_INC-202101408012 Same reporter, patient and drug / different dose and events
Information has been received from a pharmacist referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not reported. On 22-NOV-2016, the patient was administered an expired dose of RECOMBIVAX HB (lot # K011957, expiration date 24-OCT-2016; dose and route were unknown). No adverse effects were reported. Additional information is not expected as there is no consent for follow up/
Pt devel breakthrough chickenpox. "Covered from head to toe."  Lesions in mouth. Pt had fever & itching. Pt sister also covered  head to toe and also received varicella virus vaccine live. Additional info has been requested.
Left upper arm at injection site: redness, swollen, tender to touch, warm, and itchy.
full-body soreness and aches. every morning felt like I had done a cross-fit workout the day before when I hadn't. Soreness and body aches persisted for 8 months. It was 11 months before i felt back to normal
SUSPECTED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a patient (pharmacist) via other manufacturer (Pfizer) concerned a 76-year-old female of an unspecified ethnicity. The patient's height, and weight were not reported. The patient's concurrent conditions included: hypertension, diabetes, asthma, and rosemary allergy. Patient was not pregnant at the time of vaccination. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: 042A21A, expiry: unknown) dose was not reported, 1 total administered at left arm on 03-APR-2021 for covid-19 prophylaxis. Age at time of vaccination 74 years old. It was unknown whether patient had any adverse events following vaccination with first dose covid-19 vaccine ad26.cov2.s (Dose number in series 1). The patient received second dose of non-company suspect vaccine included: Pfizer Biontech (tozinameran) (Dose number in series 2) (form of admin, route of admin were not reported, batch number: FJ8762, expiry: unknown) dose was not reported, administered at left arm on 01-DEC-2021 for covid-19 prophylaxis. It was unknown whether patient had any adverse events following vaccination with second dose of non-company suspect vaccine Pfizer Biontech (Dose number in series 2). The patient received third dose of non-company suspect vaccine: Pfizer Biontech (tozinameran) (Dose number in series 3) (form of admin, route of admin were not reported, batch number: GL0446, expiry: unknown) dose was not reported, administered at right arm on 30-NOV-2022 for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (Dose number in series 3). No concomitant medications were reported.  On unspecified date in FEB-2023, the patient experienced covid-19 infection (suspected covid-19 infection) (Dose number in series 3) for which patient received non-company suspect drug Paxlovid (nirmatrelvir/ritonavir) (form of admin, route of admin, and batch number were not reported, expiry: unknown) dose and frequency were not reported from 28-FEB-2023 to 06-MAR-2023 for covid-19 treatment.  On 17-MAR-2023, after paxlovid treatment, the patient experienced covid-19 rebound infection. It was reported that, patient was not taking any other medications within 2 weeks of starting covid-19 treatment. The action taken with covid-19 vaccine ad26.cov2.s, tozinameran (Dose number in series 2), and tozinameran (Dose number in series 3) was not applicable; and action taken with nirmatrelvir/ritonavir was not reported. The patient was recovering from suspected covid-19 infection, and the outcome of revaccination with different covid-19 vaccine was not reported. This report was non-serious.
Pt recvd 3 doses of Engerix-B on 4DEC90, 2JAN91 & 31MAY91 & was found to be a non-responder;
I felt dizzy; arm for itchy; now it's all red; now it's all hot; now it's all  swollen.; This is a spontaneous report from a contactable consumer (patient). A 52-year-old non-pregnant female received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number= Unknown) via an unspecified route of administration on 17Feb2021 at 18:00 in left arm as single dose for COVID-19 immunization. Patient had no known allergies. Patient had no other medical history. Other medications (concomitant) in two weeks included estrogen and progesterone. Patient did not receive any other vaccine within four weeks of suspect vaccine. Patient did not have COVID prior vaccination and was not tested for COVID post vaccination. On 06Mar2021 at 12:00 PM, 16 days and 18 hours after first dose of vaccine, patient felt dizzy, arm for itchy and now it's all red, hot and swollen. Patient did not receive any treatment for the events. Outcome of the event was not recovered.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Pt came to flu clinic RN later in day after receiving 1st time flu shot earlier in am, stating he was feling a strange flushing sensation down his body, with a slight tightness in his upper chest.  RN took VS  BP124/72, P64, R20.  Color good, skin warm and dry, alert and oriented x3.  No injection site swelling or redness noted. Pt reasssured when told his VS were WNL.
mild headache; Immediate elevation  in blood pressure, heart rate; Immediate elevation  in blood pressure, heart rate; Very cold with uncontrollable shaking with chills,; Very cold with uncontrollable shaking with chills; Very cold with uncontrollable shaking with chills; Tiredness; extremely sleepy; burning in stomach; extreme heaviness; slight nausea; This is a spontaneous report from a contactable consumer (Patient reporting herself).   A 72-year-old non-pregnant female patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered at Left Arm on 15Apr2021 as DOSE 2, SINGLE and first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration, administered at Left Arm on 23Mar2021 12:00 as DOSE 1, SINGLE for COVID-19 immunisation in hospital. Medical history of the patient included high blood pressure, asthma and high cholesterol. The concomitant medications included 80mg valsartan, 6.25mg carvedilol and 10mg atorvastatin (Other medications in two weeks). The patient past medical history included known allergies to Dilaudid and Alleve. The patient not had covid prior vaccination and patient was not tested covid post vaccination. On 15Apr2021 at 8:30, patient had immediate elevation in blood pressure, heart rate, very cold with uncontrollable shaking with chills, extreme heaviness, tiredness and extremely sleepy, burning in stomach, slight nausea and mild headache. The adverse events resulted in visit of emergency room. Patient received IV treatment (unspecified medications). At time of this report event outcome was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. Information about lot/batch number cannot been obtained. No further information is expected.
fatiguing; chills; having trouble with his balance; tremors/shaking; vertigo; muscle weakness; dizziness; This spontaneous case was reported by a patient and describes the occurrence of BALANCE DISORDER (having trouble with his balance), TREMOR (tremors/shaking), VERTIGO (vertigo), MUSCULAR WEAKNESS (muscle weakness) and DIZZINESS (dizziness) in a 78-year-old male patient who received mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (batch no. 3032086) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     Previously administered products included for Drug use for unknown indication: Metoprolol Tartrate, Mirabegron, Omeprazole and Rosuvastatin; for Post-traumatic stress disorder: Sertraline; for Mood swings: Sertraline. Past adverse reactions to the above products included No adverse event with Metoprolol Tartrate, Mirabegron, Omeprazole, Rosuvastatin, Sertraline and Sertraline. Concurrent medical conditions included Aortic stenosis (since about 5 years ago, pretty stable during that time.), Mood swings and Post-traumatic stress disorder.    On 30-Oct-2023, the patient received sixth dose of mRNA-1273.815 (SPIKEVAX 2023-2024 PFS) (unknown route) 1 dosage form. In October 2023, the patient experienced BALANCE DISORDER (having trouble with his balance), TREMOR (tremors/shaking), VERTIGO (vertigo), MUSCULAR WEAKNESS (muscle weakness), DIZZINESS (dizziness) and CHILLS (chills). On 01-Nov-2023, the patient experienced FATIGUE (fatiguing). At the time of the report, BALANCE DISORDER (having trouble with his balance), TREMOR (tremors/shaking), VERTIGO (vertigo), MUSCULAR WEAKNESS (muscle weakness), DIZZINESS (dizziness), FATIGUE (fatiguing) and CHILLS (chills) was resolving.            It was reported that patient had no any other vaccines in the 4 weeks prior to COVID-19 vaccine.  Concomitant product use was not provided by the reporter.  It was reported that approximately 15 hours later he woke up at 3 am with chills so bad that he could not stop shaking, he put on more clothes, but he also felt muscle weakness and was having trouble with his balance, the room was spinning, like vertigo and some dizziness and it was very fatiguing. Currently he felt better, still kind of tired but better, it was still ongoing but improving. It was strange to him this reaction because he used to be in pretty good shape in spite of his age.  Treatment information was not provided.   This case was linked to MOD-2023-748020, MOD-2023-747999 (Patient Link).
Diarrhea; Vomited about 5 times; Felt like crap; This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea), FEELING ABNORMAL (Felt like crap) and VOMITING (Vomited about 5 times) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 027A21A) for COVID-19 vaccination.     The patient's past medical history included Surgery (a long time ago).   On 06-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021 at 10:30 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 10-Apr-2021, the patient experienced FEELING ABNORMAL (Felt like crap). On 10-Apr-2021 at 11:00 AM, the patient experienced VOMITING (Vomited about 5 times). On 11-Apr-2021, the patient experienced DIARRHOEA (Diarrhea). At the time of the report, DIARRHOEA (Diarrhea), FEELING ABNORMAL (Felt like crap) and VOMITING (Vomited about 5 times) outcome was unknown.            No relevant concomitant medications were provided. No treatment information was provided.
Red spot on arm warm to touch lump on neck, back pain, fatigue, short of breath, limbs felt achy, heavy. 1 to 2 hours after shot started feeling poorly, aches and neck swelling.
Patient received FLUMIST on 1-5-15 after completing screening questionnaire on which she stated she was not pregnant. Patient called office today, 1-12-15, and stated she took a pregnancy test today which was positive. Call made to CDC. They advised to call VAERS. I spoke to staff at VAERS and she advised me to tell patient to contact her health care provider and complete VAERS form. Patient informed to contact physician.
Information has been received from a nurse practitioner concerning a 66 year old female with blood pressure high and cholesterol high who in July 2008, was vaccinated with ZOSTAVAX (Merck) (lot # not provided).  Concomitant therapy included MAXIDE, ATENOLOL (manufacturer unknown), BENICAR and other unspecified medicines.  Shortly after the vaccination, the patient broke out in a rash that covered a majority of her body.  It was not vescicular but was described as involving upper and lower layers of skin.  It was like hives/welts on the upper skin and red blotches underneath.  It was very itchy.  She was stopped on her cholesterol medications with no improvement.  Her blood pressure medication was changed to one less likely to cause rash but she has very high blood pressure  readings and must be medicated.  No improvement.  It was thought to be sun related but did not respond to that therapy.  The patient went to her primary physician's office and also saw specialists.  She had a skin biopsy which was negative.  Numerous unspecified tests by dermatologists were also performed (results unknown).  At the time of the report, on 14-NOV-2008, the rash persisted.  The patient was not interested in PCR analysis.  Follow-up information has been received which indicated that the biopsy of rash are came.  The result was that the rash was reaction to scarce water and had nothing to do with ZOSTAVAX.  This one of two reports from the same  source.  Additional information is not expected.